A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)

Registry ID

B3461028

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PFIZER CANADA INC

Start date

2015-06-23

Completion date

2018-04-17

Last update

2014-07-18

Conditions

• TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

Related clinical trials

• A PHASE IIB, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CONCOMITANT USE OF EPLONTERSEN AND ALXN2220 COMPARED WITH EPLONTERSEN AND PLACEBO IN ADULT PARTICIPANTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
• CLEOPATTRA: EFFECTS OF NNC6019-0001 VERSUS PLACEBO ON CARDIOVASCULAR OUTCOMES IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTRCM)
• A PHASE 3, OPEN-LABEL, MULTICENTER, EXTENSION STUDY OF ACORAMIDIS IN PATIENTS WITH NEWLY DIAGNOSED VARIANT TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ACTEARLY OLE)
• MAGNITUDE: A PHASE 3, MULTINATIONAL, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NTLA-2001 IN PARTICIPANTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY (ATTR-CM)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AMYLOID DEPLETER ALXN2220 IN ADULT PARTICIPANTS WITH TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
• AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY OF EPLONTERSEN (ION-682884) IN PATIENTS WITH TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)

View on source registry